Results 61 to 70 of about 8,947 (130)

Hidrops fetal por infección congénita por citomegalovirus: tratamiento posneonatal prolongado con valganciclovir

Revista Chilena de Obstetricia y Ginecología, 2012
El citomegalovirus (CMV) es la infección viral congénita más frecuente con una prevalencia de 0,5% al nacimiento. La primoinfección aparece entre el 1-4% de las gestantes seronegativas.
Silvia Campos Arca, María Fernández Rial, Isabel Pardo Pumar, Cristina Luaces, José García Piñó, Eloy Moral Santamarina   +5 more
doaj  

Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients

Transplant International
Valganciclovir (VGC) is administered as prophylaxis to kidney transplant recipients (KTR) CMV donor (D)+/recipient (R)− and CMV R+ after thymoglobulin-induction (R+/TG).
Nathalie Hammer, Linard Hoessly, Fadi Haidar, Cédric Hirzel, Sophie de Seigneux, Christian van Delden, Bruno Vogt, Daniel Sidler, Dionysios Neofytos   +8 more
doaj   +1 more source

Cost-utility and budget impact analyses of valganciclovir for cytomegalovirus retinitis in patients with human immunodeficiency virus in Thailand

Journal of Pharmaceutical Policy and Practice
Background Cytomegalovirus retinitis (CMVR) is an opportunistic infection frequently seen in people living with HIV (PLHIV) and can cause blindness. Intravenous (IV) ganciclovir is a typical CMVR treatment in Thailand, but oral valganciclovir is a more ...
Tippawan Wongwian, Jatapat Hemapanpairoa, Nattanichcha Kulthanachairojana   +2 more
doaj   +1 more source

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease

Clinical Pharmacology: Advances and Applications, 2009
Heather E Vezina1,2, Richard C Brundage2, Thomas E Nevins3, Henry H Balfour Jr1,31Department of Laboratory Medicine and Pathology, 2Department of Experimental and Clinical Pharmacology, 3Department of Pediatrics, University of ...
Heather E Vezina, Richard C Brundage, Thomas E Nevins, et al   +3 more
doaj  

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis

Journal of Research in Medical Sciences, 2014
Background: Cytomegalovirus (CMV), a problematic virus in solid organ transplant recipients (SOTR) such as liver, can worsen overall mortality and transplant outcome, so its prevention and treatment is a key of success in such patients.
Siavash Vaziri, Zohre Pezhman, Babak Sayyad, Feizolla Mansouri, Alireza Janbakhsh, Mandana Afsharian, Farid Najafi   +6 more
doaj  

Association between White Matter T2 Hyper-Intense Signals in Fetal Brain Magnetic Resonance Imaging and Neurodevelopment of Fetuses with Cytomegalovirus Infection

Diagnostics
An association between subtle changes in T2 white matter hyper-intense signals (WMHSs) detected in fetal brain magnetic resonance imaging (fbMRI) and congenital cytomegalovirus (CMV) infection has been established.
Galia Barkai, Eldad Katorza, Simon Lassman, Itachi Levinberg, Chen Hoffmann, Omer Bar-Yosef   +5 more
doaj   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Comprehensive insights into cytomegalovirus anterior segment infections: A narrative review

Taiwan Journal of Ophthalmology
Cytomegalovirus (CMV) anterior uveitis (AU), a significant cause of intraocular inflammation, is increasingly recognized in immunocompetent individuals, often leading to visual morbidity if not promptly addressed.
Yih-Shiou Hwang, Po-Yi Wu, Eugene Yu-Chuan Kang, Wei-Chi Wu, Linda Yi-Hsing Chen, Chi-Chun Lai, Kyung Seek Choi   +6 more
doaj   +1 more source

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review

Infection and Drug Resistance, 2019
Guy El Helou,1,2 Raymund R Razonable1,21Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA; 2William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USAAbstract ...
El Helou G, Razonable RR
doaj  

Short and Long-Term Outcomes in Kidney Transplant Recipients with Neutropenia or Leukopenia Following CMV Prophylaxis. [PDF]

J Health Econ Outcomes Res
Turzhitsky V, Li Q, Ai L, Jootun M, Wang W, Beyer A, Moise P, Kolobova I.   +7 more
europepmc   +1 more source